Abstract Formal economic evaluation is playing an increasingly important role in health-care decision-making.This is shown by the requirementto present economic data to support applications for public reimbursement for new pharmaceuticals in Australia and the provinces of Canada, and by the appraisal process initiated by the National Institute for Clinical Excellence in the U.K.This growing role of economic analysis applies as much to the field of asthma as anywhere. This paper provides a detailed review of applied economic studies in asthma. The review is used to explore a range of methodological issues in the field including the choice of perspective and maximand, whether to use disease-specific or generic measures of outcome and whether decision-makers should receive disaggregated cost and consequence data or results that focus on an incremental cost-effectiveness ratio. It is concluded that, given the heterogeneity in decisionmakers'objectives and constraints, economic studies should be planned and executed in such a way as to maximize flexibility in how results are presented. r
INTRODUCTION
Given the limited resources available for health care and a policy decision, in most developed countries, to remove the unregulated market from the role of resource allocation, priorities need to be set in terms of which healthcare interventions and programmes should be funded. Economic evaluation is a set of formal analytical techniques to establish the e⁄ciency of alternative policy options and thereby assist with priority-setting. These methods ful¢l an increasingly important role in health service decision-making. In some countries this is imposed at a central level; for example, the need for formal economic analysis to demonstrate the value for money of new pharmaceutical products prior to public reimbursement in Canada (1) and Australia (2) . In the U.K. this 'macro' regulatory use of economic evaluation is developing with the National Institute of Clinical Excellence (3). Economic methods also have an important role in local health service decision-making F for example, in the development of hospital formularies.
The importance of formal economic analysis in asthma care is, in part, a re£ection of the burden of the disease in terms of resource cost and health. Weiss et al. estimated that the total cost of asthma in the US was $US6.2 billion in 1990, with the cost to the health-care system contributing 59% of this total (4) . In the U.K., asthma was estimated to cost society d843 million per year at 1988 prices, with total health-care costs for asthma running at d344 million per annum (5) .Whilst the costs of asthma are related to severity of disease, and the most severe asthmatics contribute a disproportionately high amount to the total economic burden of disease, signi¢cant costs are also incurred by the health-care system as a result of poor management of milder patients (6) .
Economic evaluation is also needed as a result of the development of new forms of management, such as pharmaceutical therapies, which often impose extra costs on the health-care system but promise additional health bene¢ts to patients. Despite the activity in economic analysis in asthma, the methods that have been employed have been inconsistent (7) , and there is little evidence that their results have yet to impact on decision-making. The variability in choice of methods is a re£ection of the general uncertainty regarding appropriate analytical tools in economic health care and, in particular, the choice of costs and outcomes to incorporate. This paper describes the methods of economic evaluation in asthma and critically assesses the published literature in this ¢eld. It focuses on the choice of costs and outcomes in published studies and assesses whether these endpoints are su⁄cient given the alternative objectives underlying the use of economic evaluation. An important objective of the paper is to suggest ways in which economic evaluation in asthma may improve decision-making.
PRINCIPLES OF ECONOMIC EVALUATION INHEALTH CARE De¢ning economic evaluation
Economic evaluation in health care is de¢ned as the comparison of alternative options in terms of their costs and consequences (8) . Alternative options refer to the range of ways in which health-care resources can be deployed to generate improved health in a given patient or population group; for example, pharmaceutical and surgical interventions, screening and health promotion programmes.
Health-care costs refer to the value of physical resources at the disposal of the health-care system; for example, clinical and other sta¡, capital equipment and buildings, and consumables such as drugs. In addition, non-health service resources are frequently deployed as part of the process of producing health-care, such as the time of patients and their families. Consequences represent all the e¡ects of health care programmes other than those on resources.Typically, these would include the implications of options for individuals' health, and these can be positive or negative. However, consequences also include other e¡ects that individuals may value, such as reassurance and information provision (9) .
Establishing value for money
Establishing the value for money of interventions involves aggregation of the various costs and consequences of alternative options within a comparative framework and relating the di¡erential cost between options to their differential bene¢ts. There are two alternative approaches to aggregation: cost^e¡ectiveness analysis (CEA) and cost^bene¢t analysis (CBA). Three types of CEA are used: standard CEA, cost-utility analysis (CUA) and cost-minimization analysis (CMA) ( Table 1 ). The process of aggregating costs is essentially identical in each form of analysis and straightforward given that all costs are expressed on a single monetary scale. The four forms of analysis di¡er in how they aggregate consequences. Standard CEA and CMA can only be used in speci¢c circumstances: CEA is used when only one measure of consequence is considered important or di¡ers between the options; CMA is used when evidence indicates that there are no important di¡erences between options in any non-resource consequence.
CUA and CBA are more £exible in that they o¡er methods of combining various consequences of interventions in a single bene¢t scale (Table 1) . CUA usually focuses on the various health e¡ects of options (e.g. pain, physical function, mental health) and synthesizes these, with any implications for life expectancy, onto a single scale, typically in the form of the quality-adjusted lifeyear (QALY). CBA also values multi-dimensional consequences onto a single scale but di¡ers from CUA in that the scale is represented in monetary units. In practice, CBA is rarely used in health care evaluations (10), in part due to the di⁄culties of valuing health in monetary terms.
Published economic evaluations in asthma
A literature search was undertaken using Medline, the O⁄ce for Health Economics (OHE) Health Economic Evaluations Database (HEED), the NHS Economic Evaluation Database and the Current Contents on-line databases from 1985 to June 2002, with the purpose of capturing all economic evaluations that have been published to date in asthma. Studies which failed to conduct a full economic evaluation were excluded as were studies which failed to measure both costs and consequences of treatment. Thus, studies that considered only costs with no evidence of equivalent outcomes between competing interventions were not included.
The results of this search are presented inTable 2. It is clear that health economic terminology has been subject to much misuse in the asthma literature. Some studies claim to be cost-e¡ectiveness analyses, but in practice only consider costs (11) . Others evaluate e¡ectiveness in terms of a reduction in the use of health-care resources, which are also included in the cost component of the analysis (12) . Similarly, some studies claim to be cost-bene¢t analyses but do not explicitly value consequences and are essentially cost analyses (13, 14) . Only one published study has used a true cost^bene¢t approach in the economic evaluation of asthma (15) . In this study, consequences of therapy were valued using a willingness to pay approach (16) , and the authors were able to demonstrate that budesonide was more cost^bene¢cial than placebo in patients with mild asthma. Table 2 shows a total of 33 studies published between 1985 and 2002 that met the inclusion criteria. Of these, 27 were standard CEAs, four took a disaggregated approach to costs and consequences, whilst there was one example each of CMA and CBA. Despite some methodological work in asthma (17^19) and its importance for some decision-makers, there were only two examples of CUA. Given the preponderance of CEA, the remainder of this paper focuses on this form of analysis.
DECISION RULES IN CEA
Within the framework of CEA, identifying a preferred option from among those being compared ('decision rules') involves relating di¡erences in costs to di¡erences in bene¢ts. In the case of an option being dominant (costing less and generating at least as much bene¢t, or producing greater bene¢t and being no more costly than its comparators), it is unequivocally cost-e¡ective. However, if an option generates additional bene¢ts it can still be considered cost-e¡ective even if it also increases costs. In such a situation, the option's incremental cost per additional unit of bene¢t is calculated and compared with other uses of health service resources.For example, if an incremental cost-e¡ectiveness ratio (ICER) was calculated for a new asthma drug relative to standard practice, the only way in which an assessment could be made regarding whether the additional cost of the new drug is worth incurring to reap its extra bene¢t is to compare its ICER with those of asthma treatment options not considered in the evaluation (e.g. implement a new asthma treatment or fund an asthma self-management programme).This sort of comparison can establish whether, in a resource-limited system, the independent options with a higher ICER should be scaled-down or stopped to fund the new asthma drug, with the health-care system generating a net gain in bene¢ts. Recently, it has been argued that the ICER should be replaced due to its statistical intractability and replaced by the concept of net bene¢t (20) . However, the main principles of CEA remain largely unchanged.
MEASURING COSTS AND CONSEQUENCES IN ASTHMA
Although the principles of CEA are clear, there are no ¢rm implications regarding the most appropriate measures of costs and consequences to incorporate into an analysis. In the context of economic evaluation in asthma, the variety of costs that have been considered in studies is shown in Table 2 . A range of perspectives have been taken in the literature and include studies which consider only asthma drug costs through to adoption of a full societal perspective by, for example, including productivity costs. By far, the most common costs included in asthma economic evaluations are direct health-care costs. Regardless of the types of costs included, one common failing illustrated in the literature is that the perspective taken for the analysis is rarely explicitly stated, even when the types of costs included are clearly presented.
As well as a wide range of costs included in these studies, there has been an equally large variation in measures of consequence within asthma cost-e¡ectiveness analyses (Table 3) . Even where there is some agreement across studies about the desired outcome of asthma management, there is still a considerable degree of heterogeneity in how bene¢ts are expressed.
PERSPECTIVE AND MAXIMAND
As mentioned above, any assessment of published studies with respect to their choices regarding costs and consequences needs to be clear about the appropriateness of a study's perspective (i.e. whose costs and bene¢ts are we interested in?) and its maximand (i.e. what bene¢ts are we trying to maximize from limited resources when we undertake an economic evaluation?). In essence, these are normative questions to which there is no correct technical answer. There appear to be strong arguments in favour of the health-care system seeking to maximize some measure of population health; however, individual decision-makers may have quite di¡erent ideas about the most appropriate objective of resource allocation.
The choice of perspective in an analysis is also one over which the various stakeholders in an evaluation (analysts, patients, potential patients, clinicians, managers) may have di¡erent views. There are strong arguments in favour of considering the costs and consequences of health care for all groups and individuals (societal perspective) (21, 22) . Perhaps the strongest of these arguments is that a societal perspective avoids the risk that an option is deemed cost-e¡ective despite a sub-group of the population or an organization experiencing signi¢cant negative consequences or additional costs. For example, an education programme for asthmatics may appear cost-e¡ective when only health service costs are considered, but perhaps only because the costs to patients (in terms of, for example, the time costs of attending a education sessions) are ignored. However, as with the choice of maximand, the individual decisionmaker may have a very narrow perspective. For example, on the cost side, they may only be interested in the impact of a new drug on the pharmacy budget.
Measuring consequences
Consequence measures in asthma Table 3 shows that there is consistency in economic studies in asthma regarding the perspective they have employed: the individual with asthma is always the focus; however, the table shows considerable variation in the measures used including symptoms, exacerbations and more formal health-related quality of life (QoL) measures. Table 3 identi¢es11di¡erent groups of consequence measures used in economic evaluation is asthma and, even within these groups, there remains variation in the speci¢c measures used. For example, although the majority of cost-e¡ectiveness studies chose to focus on symptoms as their main measure of consequence, the process of weighting and aggregation di¡ered markedly between studies. Variants included symptom-free days (with the actual de¢nition of a day unclear), symptomfree 24 -h periods and time to successful control.
The variability in consequence measure probably partially re£ects the fact that the objectives of asthma interventions di¡er or have multiple objectives. For example, bronchodilators have a mode of action that is more focused on short-term alleviation of symptoms and improvement in lung function, so it would seem appropriate for endpoints measuring these facets to predominate in evaluations of these interventions. On the other hand, measures such as reduction in exacerbations, improvement in health-related QoL and longer term improvements in lung function and symptoms tend to be more important for prophylactic therapies such as inhaled corticosteroids.
Asthma-speci¢c measures ofconsequence
The lack of consistency in consequence measures used in studies has important implications for the usefulness of economic data to decision-makers. As described above, when a new therapy is more costly but also more bene¢cial than its comparator, an incremental cost per additional unit of bene¢t is calculated to provide a decisionmaker with an indication of how much more patients are getting for the additional cost involved. To help in the decision-making process, the ICER should be compared with the same ratio calculated in other (i.e. independent) evaluations.
For decision-makers to be able to make full use of the data generated by such studies, there needs to be agreement on the appropriate perspective and maximand, and each study has to employ a common measure of consequence that relates clearly to the maximand. If it is assumed, for example, that the objective of caring for all asthma patients is to maximize, from the limited resources available in that area, the proportion of patients' lives without symptoms, and if it is also agreed that the a symptom-free day (SFD) could be de¢ned and used in all CEA in asthma, then each study would compare its alternative treatments in terms of their costs and rates of SFD. A dominant treatment (e.g. one which is less costly than its comparator(s) and generates at least as many SFDs) would clearly be cost-e¡ective and worth funding. If the more costly therapy also achieved more SFDs, its ICER would be calculated (the incremental cost per additional SFD). If a number of studies in asthma had already reported similar ratios, it would be possible for decisionmakers to compare ICERs and assess whether resources should be re-allocated in the area.
There are limitations to this focus on an asthma-speci¢c maximand and measure of consequence. The ¢rst is the relevance of a single measure of consequence to all patients with asthma. As noted above, di¡erent types of therapy for di¡erent sub-groups of asthmatics are likely to have a variety of clinical objectives. It may be the case, for example, that minimizing symptoms and the use of an SFD as the measure of consequence is not appropriate for all sub-groups of asthmatics. Furthermore, an SFD may be interpreted di¡erently between individuals: for example, a severe asthmatic may de¢ne a SFD in quite a di¡erent way to a mild asthmatic. In other words, it may be very di⁄cult to identify a single maximand and common measure of consequence in CEA in asthma.
A generic measure of health
A second limitation of an asthma-speci¢c maximand is that there may be good reason to fund more costly but more bene¢cial therapies for asthma by re-allocating budgets from outside of that particular clinical area. This cross-programme resource allocation is more clearly related to a broader maximand than symptoms in asthma. If the cost-e¡ectiveness of new asthma treatments is to be compared with that of interventions in a range of different specialties and disease areas, it is necessary to agree on a broad maximand, such as health in general.
With such a maximand, a new drug for asthma (which is more costly and more bene¢cial than standard therapy) would be considered cost-e¡ective if its incremental cost per extra unit of health gain compared favourably with health-care interventions inside or outside asthma. In order to facilitate cross-programme resource allocation of this sort using a maximand of overall health, it is necessary to incorporate generic measures of health gain into CEA.The use of the QALYas a measure of consequence, as described earlier and in Table 1 , represents the branch of CEA which focuses on supporting the broader maximand of health. The process of estimating QALYs in a given study is not a subject for detailed consideration here and is covered elsewhere (8, 23, 24) . In brief, a popular approach to measuring QALYs involves measuring patients' health-related quality of life (HRQoL) (within a trial or observational study) using a generic measure that describes health in terms that are not associated with a speci¢c disease or intervention. It would then be necessary to score this instrument in such a way that a single index (often called a value or utility) is derived to re£ect a patient's HRQoL at any point in time running from 0 (equivalent to death) to 1 (equivalent to good health). This scoring process involves weighting the relative importance of di¡erent dimensions of HRQoL, and of di¡erent items within each dimension, using utilities or preference scores,.This is inherently subjective and will re£ect the di¡erent preferences of individuals.
A number of generic 'utility instruments' now exist in health care including the EuroQol (EQ) 5D (25), Health Utilities Index (HUI) III (26) , and Quality of Wellbeing (QWB) Scale (24) . Each of these instruments uses the preferences of the general public to derive utility weights for di¡erent domains and items in the HRQoL scale, based on the view that, as the ultimate payers for health care, it is societal views that should count in this respect (21) . An alternative way to measure QALYs is to elicit utilities directly from patients relating to their own state of health at a given time point. In a recent authoritative review of good methodology in economic evaluation (21) , the use of societal utilities was preferred, and this has been mirrored in NICE's technical guidance on economic evaluation (27). AsTable 2 shows, there are two examples of the use of QALYs as a measure of consequence in economic evaluations in asthma (28, 29) . In both cases, utilities were elicited directly from patients, although Paltiel et al. (28) also used the HUI as a sensitivity analysis. The limited use of CUA in asthma is, in part, likely to be due to the fact that QALY-based measures of consequence are inevitably less sensitive to clinical change than asthma-speci¢c measures. Generic classi¢cations of HRQoL are by their nature not as focused on the speci¢c impact of a disease or its treatments from the patient's perspective as a disease-speci¢c measure. For this reason, most studies have focused on asthma-speci¢c measures of consequence in the hope of re£ecting clinically important changes, despite the fact that this is of limited value for cross-programme resource allocation.
A second reason why the use of QALYs has been rare in asthma studies is the lack of consensus, on the part of decision-makers, that health is the appropriate maximand and that the QALY is the relevant measure of health in applied studies. Decisions need to be taken at the 'top of the service' regarding resource allocation between specialties and programmes, and here a health maximand, with QALYs as the best currently available expression of that in evaluative studies, would seem appropriate.This explains NICE's preference for the QALY (27). However, decisions on di¡erent types of resource allocation need to be made lower down in the system, and QALYs may be less relevant here. For example, there is evidence that currently general practitioners do not value the QALYas an ideal maximand in health-care decision-making (30) .
A third reason for the limited use of QALYs in asthma may be the limited opportunities to evaluate QALY endpoints within the framework of traditional drug development. The majority of published economic analyses to date have been conducted as part of clinical trials, whose primary aim is regulatory approval or demonstration of superior clinical e⁄cacy. From Table 2 , it is clear that many of these trials are of relatively short duration and this, coupled with the perceived lack of sensitivity of generic QALYs, may have resulted in the limited use ofQALYs in applied studies in asthma. If there is to be an increase in the use of this measure of bene¢t, it will require greater investment in longer term, properly powered studies that have economic evaluation as a primary aim.
Given the heterogeneity in the type of decisions that need to be taken in health care systems, there appears to be a strong argument for economic studies in asthma to take a pragmatic approach and o¡er a range of consequence measures and, where appropriate, generate ICERs using each of these. In other words, for cross-programme resource allocation, the presentation of cost-effectiveness using QALYs is desirable and ideally should be factored into studies. However, this should be undertaken in parallel with asthma-speci¢c measures of conse-quence like SFDs, the use of which may support decisionmaking within specialties and programmes.
Furthermore, if decision-makers are unwilling to be explicit about a maximand for CEA, then it is important for one of the outputs of studies to be a disaggregated description of costs and all consequences.Often referred to as cost-consequences analysis (8) , this form of evaluation essentially presents a balance sheet of the costs and consequences of the two or more interventions under comparison.
Measuring costs
Compared to the issues associated with the measurement of consequences in economic evaluation, cost measurement is less contentious. However, some important methodological uncertainties exist including how to estimate accurate unit costs and the appropriate vehicle for resource allocation measurement. These are discussed fully elsewhere (8, 21) . Some methodological issues in costing are particularly relevant to the economic appraisal of asthma interventions. These include the choice of perspective, valuation of time costs and the appropriate time horizon.
Cost perspective
As noted above, there are strong reasons to take a societal perspective on costs. Of those economic studies in asthma (Table2),12 studies included costs of lost productivity and could be argued to have adopted a broad societal perspective. One reason why some studies took a narrower perspective than societal is probably the perception that all or a sub-group of health-care decisionmakers are not interested in costs other than those falling on the health-care system. As with consequences, it is likely that decision-makers at the various levels within the system have di¡erent attitudes to the appropriate cost perspective.
Given the variety of cost implications that are likely to be of interest to decision-makers and the importance of checking that a health-care intervention is not deemed cost-e¡ective because not all its resource cost implications have been included, a variety of perspectives should be adopted in economic studies in asthma.There is again a strong case to present decision-makers with disaggregated information on the resource implications of interventions and the cost of those resources within a costĉ onsequences analysis.This allows decision-makers to include those costs they think appropriate in reaching a decision. However, it is also important for data on all costs to be made public and for the decisions that are ultimately taken to be assessed against a societal perspective on costs.
Valuing time costs
If, as argued above, a societal perspective should be part of economic studies in asthma, an important non-healthcare cost is the value of the time of patients and carers that is a¡ected by asthma and interventions to treat it. Four time costs are relevant here: patients' healthy time that is lost due to the morbidity and mortality associated with asthma; the time patients put into the process of receiving health care (e.g. visiting a clinic); and the time carers put into caring for friends and relatives with asthma.
In principle, measuring these time inputs can be undertaken in clinical trials and observational studies. It is their valuation which raises di⁄cult methodological problems. These issues have been discussed fully elsewhere (21, 31 Appropriate methodology in this area is currently unclear and considerable research is required. In an applied study in asthma, therefore, it would be appropriate to use as many valuation techniques as possible and to compare their implications for the conclusions of a study.
Appropriate time horizon
The choice of time horizon is important in any study. In a CEA, appropriateness should be judged according to the time-point at which the options under consideration can be expected not to di¡er in terms of their costs and consequences. Inevitably, there will be marked uncertainty about this time-point, especially in the context of a chronic disease such as asthma, where symptoms and treatment may continue for many years. The problem is accentuated in asthma by the short-term duration of many of the clinical trials that provide the data for CEA. As shown in Table2, the duration of trial-based studies ranges from just 4 weeks to 4 years. Unless it can be assumed that, after these points, di¡erential costs and bene¢ts do not alter, shorter time horizons are likely to be inappropriate, although the minimum acceptable time frame for economic analysis in asthma is somewhat unclear.
In future, economic analysis of asthma interventions will have to include alternative or complementary methods to short-term regulatory trials. These will include long-term pragmatic trials, decision modelling to extrapolate trial results over a longer time horizon and the use of large longitudinal databases to generate long-term resource use and consequence data to populate models. Longer term pragmatic trials probably o¡er the best opportunity of measuring QALY bene¢ts of asthma treatments as there is likely to be a favourable time horizon and the more naturalistic setting may reduce'noise' associated with trial e¡ects.
CONCLUSIONS
National guidelines for economic evaluation in Canada and Australia are spreading across Europe with initiatives established or in development in countries such as The Netherlands, Ireland and the U.K. Following increasing national requirements, economic evidence is also becoming key data for health-care providers such as HMOs (32) . It is clear that the importance of formal economic analyses will only increase.
Economic evaluations of health-care technologies should ideally facilitate better health-care decision-making by explicitly identifying, measuring and valuing the costs, consequences and trade-o¡s between competing interventions. However, to enable competing interventions to be compared and evaluated, there is a need for a level of comparability across methodologies which is currently lacking in the asthma literature.This is particularly evident in the choice of consequences reported. Even when similar measures of e¡ectiveness are used there is a lack of consistency over de¢nition as well as over the methodology used to collect the evidence.
Given the objective of satisfying the needs of di¡erent decision-makers at alternative levels in the health-care system, but also the normative strength of health maximization as the primary objective of the system, it is important to develop an economic analysis with a range of measures of consequence. The ¢rst step, however, should be to take a disaggregated cost-consequence approach, with a 'balance sheet' of all relevant costs and a full range of consequences reported.
Finally, an issue that will require further consideration is who should be undertaking and funding economic evaluation studies. Manufacturers of health-care technologies, such as pharmaceutical companies, represent an important source of economic studies (either directly or through the funding of other groups). Furthermore, the decisions of reimbursement authorities, such as those in Canada and Australia, are largely based on submissions from manufacturers. It has been argued that economic evaluations are more susceptible to bias than clinical studies (33) . Although this point is open to debate, reimbursement authorities are likely to have to fund independent groups either to undertake new economic studies or to critically appraise submissions.
